Are we close to targeted treatments for Huntington’s disease? COMMENT

Czech version

Authors: doc. MUDr. Matej Škorvánek; Phd
Authors‘ workplace: Košice ; Neurologická klinika, LF UPJŠ a UNLP
Published in: Cesk Slov Neurol N 2020; 83/116(3): 242
Category:

Sources

1. Frank S, Testa CM, Stamler D et al. Effect of deutetrabenazine on chorea among patients with huntington disease a randomized clinical trial. Jama J Am Med Assoc 2016; 316 (1): 40–50. doi: 10.1001/jama.2016.8655.

2. Mestre TA. Recent advances n the therapeutic development for Huntington disease. Park Relat Disord 2019; 59: 125–130. doi: 10.1016/j.parkreldis.2018.12.003.

3. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB et al. Targeting Huntingtin expression in patients with Huntington‘s disease. N Engl J Med 2019; 380 (24): 2307–2316. doi: 10.1056/NEJMoa1900907.

4. Investigators HSGRH. Safety, tolerability, and efficacy of PBT2 in Huntington‘s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015; 14 (1): 39–47. doi: 10.1016/S1474-4422 (14) 70262-5.

5. Reilmann R, Squitieri F, Priller J et al. Safety and tolerability of selisistat for the treatment of huntington‘s disease: results from a randomised, double-blind, placebo-controlled phase II trial. J Neurol Neurosurg Psychiatr 2014; 82 (10 Suppl): A102.

6. A. Biotech. [online]. Dostupné z URL: https: //www.activebiotech.com/en/media/ pressreleases/?id=2208124&date=1533024900.